---
layout: default
title: Valproic Acid
parent: 僅模型預測 (L5)
nav_order: 345
evidence_level: L5
indication_count: 10
---

# Valproic Acid
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Valproic Acid: From Epilepsy to Trigeminal Nerve Neoplasm

## One-Sentence Summary

Valproic acid (VPA) is a well-established antiepileptic and mood-stabilizing drug, widely recognized for its use in epilepsy, bipolar disorder, and migraine prophylaxis.
The TxGNN model predicts it may be effective for **Trigeminal Nerve Neoplasm** — drawing on VPA's known HDAC inhibitor activity and broad antitumor potential —
however, this direction is currently supported by **0 clinical trials** and only **1 indirectly related publication**, placing this prediction at the lowest evidence tier.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Epilepsy (established clinical use; no Philippines registration on record) |
| Predicted New Indication | Trigeminal Nerve Neoplasm |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| Philippines Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the evidence pack. Based on known pharmacology, valproic acid operates through at least four established mechanisms: (1) enhancement of GABAergic inhibition by increasing GABA synthesis and reducing its degradation; (2) blockade of voltage-gated sodium channels to suppress repetitive neuronal firing; (3) inhibition of T-type calcium channels to interrupt thalamocortical synchronization; and (4) — most relevant to this oncology prediction — inhibition of histone deacetylases (HDACs), which promotes chromatin remodeling, cell cycle arrest, and pro-apoptotic signaling.

The TxGNN model likely draws this prediction through indirect knowledge graph linkages connecting VPA's HDAC inhibitor activity to broader neural tumor biology. Trigeminal nerve neoplasms are rare peripheral nerve sheath tumors (primarily schwannomas and neurofibromas), and while VPA's HDAC inhibitor properties have demonstrated antineoplastic potential in glioma models (see PMID 39786974, PMID 26985579 in adjacent indications), no direct clinical or preclinical research exists for this specific tumor histotype. The single retrieved publication concerns Sturge-Weber syndrome — a neurovascular disorder sometimes managed with antiepileptics — and does not address trigeminal nerve neoplasm.

The mechanistic chain (HDAC inhibition → chromatin remodeling → tumor suppression) is biologically coherent but remains an extrapolation at this stage. This prediction is best understood as a hypothesis-generating signal from the model, not actionable clinical evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|------|------|---------|-------------|
| [9157801](https://pubmed.ncbi.nlm.nih.gov/9157801/) | 1997 | Case Series | Anales Españoles de Pediatría | 14-case review of Sturge-Weber syndrome over 25 years; evaluates clinical characteristics, disease progression, and antiepileptic treatment response. VPA is used in a neurovascular context — not directly relevant to trigeminal nerve neoplasm. |

---

## Philippines Market Information

No registered products found in the Philippines FDA database for Valproic Acid. No licenses on record.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a high TxGNN prediction score (99.97%), the evidence base for VPA in trigeminal nerve neoplasm is entirely absent — there are zero clinical trials and only one tangentially related case series. The prediction is mechanistically plausible via VPA's HDAC inhibitor activity but cannot be actioned without dedicated supporting research.

**To proceed, the following is needed:**
- Preclinical studies in trigeminal nerve tumor cell lines (schwannoma, neurofibroma) to confirm HDAC inhibitor activity and cytostatic effects of VPA
- Mechanism of action data retrieval from DrugBank API to formally characterize VPA's HDAC inhibitory profile
- Package insert review (TFDA/FDA Philippines label) for warnings, contraindications, and drug interaction profile
- Assessment of VPA's safety in the context of concurrent chemotherapy or radiotherapy for nerve sheath tumors
- If preclinical evidence is established, consider a basket trial design covering rare peripheral nerve tumors where VPA HDAC inhibition could be tested alongside standard-of-care regimens
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

